B-Cell Acute Lymphoblastic Leukemia Arising in Patients With Multiple Myeloma Achieving Sustained MRD-Negative Remission With Blinatumomab (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-745; "Case Description: We report a patient with long-standing MM who developed Philadelphia chromosome-negative B-ALL approximately 6 years after the initialMMdiagnosis following prolonged exposure to immunomodulatory therapy, including lenalidomide for 19 months during induction and maintenance and thalidomide for more than 3 years. This case highlights a diagnostically challenging scenario in which clinical deterioration in MM can mask the emergence of a biologically distinct secondary hematologic malignancy. It further supports the possibility of B-ALL as a clonally independent second primary neoplasm potentially associated with prolonged immunomodulatory exposure, even in the absence of prior transplantation or intensive cytotoxic therapy. Moreover, this report underscores the importance of early bone marrow evaluation in patients with MM who present with unexplained cytopenias; the efficacy of blinatumomab in achieving deep and durable molecular remission in this..."
Clinical • Minimal residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology
|
|
Raghda Tarek MD 1,2; Rahma Abdelaziz MD 3; Shalini Chhabra MD 4; Mohamed Hegazi MD PhD 4
|